Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 113

1.

New neoplasm during GH replacement in adults with pituitary deficiency following malignancy- a KIMS analysis.

Krzyzanowska-Mittermayer K, Mattsson AF, Maiter D, Feldt-Rasmussen U, Camacho-Hübner C, Luger A, Abs R.

J Clin Endocrinol Metab. 2017 Dec 7. doi: 10.1210/jc.2017-01899. [Epub ahead of print]

PMID:
29228199
2.

Relative risks of contributing factors to morbidity and mortality in adults with craniopharyngioma on GH replacement.

Yuen KCJ, Mattsson AF, Burman P, Erfurth EM, Camacho-Hubner C, Fox JL, Verhelst J, Geffner ME, Abs R.

J Clin Endocrinol Metab. 2017 Sep 29. doi: 10.1210/jc.2017-01542. [Epub ahead of print]

PMID:
29029108
3.

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.

Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R; Pasireotide B2305 Study Group.

Pituitary. 2015 Oct;18(5):604-12. doi: 10.1007/s11102-014-0618-1.

4.

[Buttocks enhancement using silicone implants: a national practices assessement about 538 patients].

Mezzine H, Khairallah G, Abs R, Simon E.

Ann Chir Plast Esthet. 2015 Apr;60(2):110-6. doi: 10.1016/j.anplas.2014.10.003. Epub 2014 Oct 31. French.

PMID:
25435070
5.

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group.

Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014 Mar 27.

PMID:
24533697
6.

Primary treatment regimen and diabetes insipidus as predictors of health outcomes in adults with childhood-onset craniopharyngioma.

Yuen KC, Kołtowska-Häggström M, Cook DM, Fox JL, Jönsson PJ, Geffner ME, Abs R.

J Clin Endocrinol Metab. 2014 Apr;99(4):1227-35. doi: 10.1210/jc.2013-3631. Epub 2014 Jan 29.

PMID:
24476077
7.

Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction.

Yuen KC, Koltowska-Häggström M, Cook DM, Fox JL, Jönsson PJ, Geffner ME, Abs R.

Eur J Endocrinol. 2013 Sep 17;169(4):511-9. doi: 10.1530/EJE-13-0280. Print 2013 Oct.

8.

High variability in baseline urinary free cortisol values in patients with Cushing's disease.

Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BM; Pasireotide B2305 Study Group.

Clin Endocrinol (Oxf). 2014 Feb;80(2):261-9. doi: 10.1111/cen.12259. Epub 2013 Jul 15.

9.

Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis.

Abs R, Mattsson AF, Thunander M, Verhelst J, Góth MI, Wilton P, Kołtowska-Häggström M, Luger A.

Eur J Endocrinol. 2013 Feb 15;168(3):297-305. doi: 10.1530/EJE-12-0807. Print 2013 Mar.

10.

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly.

Verhelst J, Velkeniers B, Maiter D, Haentjens P, T'Sjoen G, Rietzschel E, Corvilain B, Abrams P, Nobels F, Abs R, Bex M.

Eur J Endocrinol. 2013 Jan 17;168(2):177-84. doi: 10.1530/EJE-12-0753. Print 2013 Feb.

11.

Overall and cause-specific mortality in GH-deficient adults on GH replacement.

Gaillard RC, Mattsson AF, Akerblad AC, Bengtsson BÅ, Cara J, Feldt-Rasmussen U, Koltowska-Häggström M, Monson JP, Saller B, Wilton P, Abs R.

Eur J Endocrinol. 2012 Jun;166(6):1069-77. doi: 10.1530/EJE-11-1028. Epub 2012 Mar 28.

12.

A 12-month phase 3 study of pasireotide in Cushing's disease.

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group.

N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780.

13.

Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study.

Luger A, Mattsson AF, Koltowska-Häggström M, Thunander M, Góth M, Verhelst J, Abs R.

Diabetes Care. 2012 Jan;35(1):57-62. doi: 10.2337/dc11-0449. Epub 2011 Nov 10.

14.

Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis.

Verhelst J, Mattsson AF, Luger A, Thunander M, Góth MI, Koltowska-Häggström M, Abs R.

Eur J Endocrinol. 2011 Dec;165(6):881-9. doi: 10.1530/EJE-11-0599. Epub 2011 Oct 3.

15.

Lessons learned from 15 years of KIMS and 5 years of ACROSTUDY.

Luger A, Feldt-Rasmussen U, Abs R, Gaillard RC, Buchfelder M, Trainer P, Brue T.

Horm Res Paediatr. 2011;76 Suppl 1:33-8. doi: 10.1159/000329156. Epub 2011 Jul 21.

PMID:
21778746
16.

Panhypopituitarism apparently caused by hypophysitis masking a rapid development of a craniopharyngioma. A case report.

Joosen P, Abrams P, Verhelst J, Parizel PM, Salgado R, Abs R.

Acta Clin Belg. 2010 Mar-Apr;65(2):133-5.

PMID:
20491365
17.

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM; Pasireotide Acromegaly Study Group.

J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9. doi: 10.1210/jc.2009-2272. Epub 2010 Apr 21.

PMID:
20410233
18.

Treatment of adult growth hormone deficiency: who, why and how? A review.

Alexopoulou O, Abs R, Maiter D.

Acta Clin Belg. 2010 Jan-Feb;65(1):13-22. Review.

PMID:
20373593
19.

Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency.

Kołtowska-Häggström M, Geffner ME, Jönsson P, Monson JP, Abs R, Hána V, Höybye C, Wollmann HA.

J Clin Endocrinol Metab. 2010 Jun;95(6):2646-54. doi: 10.1210/jc.2009-2013. Epub 2010 Mar 24.

PMID:
20335451
20.

Cardiovascular risk factors in hypopituitary GH-deficient adults.

Verhelst J, Abs R.

Eur J Endocrinol. 2009 Nov;161 Suppl 1:S41-9. doi: 10.1530/EJE-09-0291. Epub 2009 Aug 14. Review.

Supplemental Content

Loading ...
Support Center